Best-Value Biological Medicine: Tocilizumab

The HSE-Medicines Management Programme (MMP) is undertaking a formal consultation phase as part of the process for the identification of a best-value biological (BVB) medicine for tocilizumab.

The MMP roadmap for the prescribing of best-value biological (BVB) medicines in the Irish healthcare setting (PDF, size 471.1 KB, 2 pages) outlines the criteria that may be considered by the MMP in identifying the BVB medicine for tocilizumab.

Submissions are invited from all relevant stakeholders, and should be emailed to mmp@hse.ie by 1pm on Monday 27 May 2024.